These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 19486187)

  • 21. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
    HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
    Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
    AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    Prasitsuebsai W; Cressey TR; Capparelli E; Vanprapar N; Lapphra K; Chokephaibulkit K
    Pediatr Infect Dis J; 2012 Apr; 31(4):389-91. PubMed ID: 22146740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
    Dailly E; Allavena C; Grégoire M; Reliquet V; Bouquié R; Billaud E; Hernando H; Bouchez S; Deslandes G; Hall N; Jolliet P; Raffi F
    J Antimicrob Chemother; 2015 Dec; 70(12):3307-10. PubMed ID: 26271944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.
    Arribas J; Hill A; Xi N; van Delft Y; Moecklinghoff C
    J Antimicrob Chemother; 2012 Jul; 67(7):1804-6. PubMed ID: 22454490
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
    Vreeman RC; Nyandiko WM; Liechty EA; Busakhala N; Bartelink IH; Savic RM; Scanlon ML; Ayaya SO; Blaschke TF
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):277-86. PubMed ID: 25140906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Ramachandran G; Hemanthkumar AK; Rajasekaran S; Padmapriyadarsini C; Narendran G; Sukumar B; Sathishnarayan S; Raja K; Kumaraswami V; Swaminathan S
    J Acquir Immune Defic Syndr; 2006 May; 42(1):36-41. PubMed ID: 16639340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
    Svensson E; van der Walt JS; Barnes KI; Cohen K; Kredo T; Huitema A; Nachega JB; Karlsson MO; Denti P
    Br J Clin Pharmacol; 2012 Sep; 74(3):465-76. PubMed ID: 22300396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
    Parienti JJ; Peytavin G; Reliquet V; Verdon R; Coquerel A
    Clin Infect Dis; 2010 Jun; 50(11):1547-8. PubMed ID: 20433360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.